THREE CREATIVE, ENTREPRENEURIAL CHEMISTS WANTED
Sopharmia Inc. is a Missouri-based company working to pioneer a new class of β-lactam
antibiotics, which use a latent reactive group
to combine β-lactamase inhibition together
with cephalosporin, monobactam or
carbapenem class antibiotic activity.
Sopharmia is completing a $3 million seed
financing by end of January, and will set up
a Montreal chemistry lab. with four
employees in February. Sopharmia was
founded by Larry D. Sutton, MD, PhD, who
will provide SAR guidance, compound design
and leadership to the Montreal team, from
the company`s base outside Kansas City,
Missouri. Larry is supported by former GSK
senior chemist Rick Keenan, PhD, who is a member of the SAB. A molecular modeller will also
support the team.
Sopharmia will hire a team of four bench chemists to develop a lead cephalosporin class
compound plus backup:
Senior Chemist: PhD plus ≥5 years` of industrial synthetic experience; knowledge of βlactams a plus but not required
2 Chemists:


One PhD graduate looking for an industrial post-doc.
MSc with ≥ 2 years` synthetic experience or Bachelor`s degree with ≥ 4 years`
synthetic experience
The 4th team member is an MSc chemist with 17 years` experience in the Biotech./
pharmaceutical industry (including Methylgene) who has provided synthesis services to
Sopharmia for over 2 years, under contract with Chemzon Scientific Inc.
We are looking for individuals who want to make a difference by developing drugs effective
against resistant pathogens, who will thrive in an entrepreneurial environment with shared
goals. Contact: Michael Atkin, board chair, michael@sopharmia.com or (514) 213-4456.
Info.: http://Sopharmia.com and 2014 ICAAC poster, abstract available at
http://www.icaaconline.com/php/icaac2014abstracts/data/papers/2014/F-956.htm
Dec. 2014